Director, Energy Biosciences Inst., UC Berkeley
Strategic Advisor, Qliance Medical Management
Professor of Media Management, Syracuse University
Founder, Khosla Ventures
Managing Dir. of Life Sciences, Hercules Technology Growth Capital
Former executive vice president of R&D, Amgen.
Director, Intel Capital
Co-creator, TEDMED
|
RXi Pharmaceuticals (NASDAQ: RXII), the Worcester, MA-based developer of RNA interference drugs, said today that Noah Beerman has replaced Tod Woolf as president and CEO. Beerman, 47, was most recently chief business officer of Indevus Pharmaceuticals. The company said the leadership switch was part of a succession plan as it looks to advance into product development. Woolf will remain on the company’s scientific advisory board.
Boston · 6/14/12
8:30 am - 5:00 pm
Xconomy offers a number of ways to subscribe for free!
Subscribe Now
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc. Xconomy is a registered service mark of Xconomy, Inc. All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
